had no protective effect.
Toxoplasma gondii is one of the major opportunistic agents causing infections in immunocompromised individuals, particularly in those with AIDS (3, 6, 9) . Treatment of the infection with the combination pyrimethamine-sulfonamide may result in strong adverse reactions requiring discontinuation of the treatment before cure has been achieved (5, 6) . Because AIDS patients with toxoplasmosis, particularly toxoplasmic encephalitis, must be maintained on prolonged therapy to prevent recrudescence of the infection, it is important to develop safe and effective therapeutic regimens as an alternative to the pyrimethamine-sulfonamide combination (3, 6) . We have previously demonstrated that the macrolide antibiotic azithromycin has potent activity against T. gondii in mice (2) . Further observations have indicated that its activity is significantly superior to those of other macrolide antibiotics which have been used to treat human toxoplasmosis (1, 4) . In addition, work from our laboratory has demonstrated that gamma interferon (IFN--y) has protective activity against murine toxoplasmosis (7, 8) and has a critical role as a mediator of host immunity in infections with T. gondii (10) . Thus, it was considered of interest to investigate the activity of the combination IFNy-azithromycin in the treatment of murine toxoplasmosis.
Azithromycin ( groups B and C. Treatment with azithromycin was started 24 h after infection. These doses of rMuIFN-y and azithromycin were used because preliminary experiments showed them to be optimal for this type of experiment. In repeated expenments none of these doses, when used alone, protected more than 10o of mice against death caused by the inoculum of T. gondii employed in the study. Three experiments were performed at different times with a total of 90 mice. The results of one of two experiments with identical results are shown in Fig. 1 . Protection induced by the combination rMuIFN-y--azithromycin was significantly higher than protection induced by either azithromycin alone or rMuIFN--y alone. Thus, at the time when 100% of mice treated with rMuIFN--y alone were dead, 901% of the mice treated with the combination rMuIFN-y-azithromycin were alive (P < 0.01, Student's t test). Similarly, at the time when 90%6 of the mice treated with azithromycin alone were dead, only 20% of those treated with the combination IFN-y--azithromycin had died (P < 0.05). Thirty days after infection, when the experiment was terminated, only 1 of 10 mice treated with azithromycin alone was alive, whereas 4 of 10 mice treated with the combination were alive. None of the mice treated with IFN-y alone survived longer than 9 days. These results demonstrate that in murine toxoplasmosis, the combination rMuIFN--azithromycin provides significant protection against death compared with treatment with either of these agents alone. In other reports (2, 4) , it was demonstrated that, by using the model employed in this study, significant protection was achieved with an azithromycin dose of 200 mg/kg per day for 10 days. A dose of 5 x 104 U of IFN--y induced significant protection in mice infected with T. gondii C56 (8) . In the present study, a similar dose did not protect mice infected with the more virulent RH strain. A dose of IFN--y twice as high as that used in the present study also was not protective (1) . Although there are a number of limitations which prevent extrapolating results obtained with murine models to the situation in humans, the results described above are relevant in the search for alternative therapies for treatment of toxoplasmosis in immunocompromised hosts.
